KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medtronic (MDT) Assets (2016 - 2026)

Medtronic's Assets history spans 13 years, with the latest figure at $91.5 billion for Q1 2026.

  • On a quarterly basis, Assets rose 1.68% to $91.5 billion in Q1 2026 year-over-year; TTM through Jan 2026 was $91.5 billion, a 1.68% increase, with the full-year FY2025 number at $91.7 billion, up 1.89% from a year prior.
  • Assets hit $91.5 billion in Q1 2026 for Medtronic, roughly flat from $91.3 billion in the prior quarter.
  • Over the last five years, Assets for MDT hit a ceiling of $94.1 billion in Q1 2023 and a floor of $89.7 billion in Q3 2024.
  • Historically, Assets has averaged $91.1 billion across 5 years, with a median of $90.9 billion in 2023.
  • Biggest five-year swings in Assets: fell 5.62% in 2022 and later rose 2.54% in 2023.
  • Tracing MDT's Assets over 5 years: stood at $93.2 billion in 2022, then decreased by 3.38% to $90.1 billion in 2023, then dropped by 0.05% to $90.0 billion in 2024, then rose by 1.45% to $91.3 billion in 2025, then rose by 0.15% to $91.5 billion in 2026.
  • Business Quant data shows Assets for MDT at $91.5 billion in Q1 2026, $91.3 billion in Q4 2025, and $91.0 billion in Q3 2025.